Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | COMET: patient-reported outcomes in active monitoring versus GCC for DCIS

Puneet Singh • 13 Dec 2024
SABCS 2024
Breast Cancer
COMET

Puneet Singh, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the patient-reported outcomes (PROs) from the COMET trial (NCT02926911), which compared active monitoring (AM) with surgical management in low-risk ductal carcinoma in situ (DCIS). No significant negative outcomes were reported regardless of treatment arms, providing valuable insights into patient-centered care for low-risk DCIS. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Puneet Singh

COMET: early oncologic outcomes in active monitoring or surgery in DCIS
1:11
COMET: early oncologic outcomes in active monitoring or surgery in DCIS
Puneet Singh • 13 Dec 2024
INSEMA: non-inferiority of avoiding SLNB in early breast cancer
1:26
INSEMA: non-inferiority of avoiding SLNB in early breast cancer
Puneet Singh • 13 Dec 2024

Related Videos

Highlights in brain metastasis research at ESMO 2026
1:31
Highlights in brain metastasis research at ESMO 2026
Ariane Steindl • 26 Oct 2026
Intraoperative ultrasound assessment of sentinel nodes in breast cancer
2:14
Intraoperative ultrasound assessment of sentinel nodes in breast cancer
Ludovica Pitoni • 4 Nov 2026
AIUR: surgical glove compression for paclitaxel-induced neuropathy in breast cancer
4:38
AIUR: surgical glove compression for paclitaxel-induced neuropathy in breast cancer
Young-Joon Kang • 25 Oct 2026
How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals